Please check your internet connection and try again.
## Sompraz hp (Somatostatin analog)
### Overview
Sompraz hp is a long-acting synthetic analog of the hormone somatostatin. It is primarily used to inhibit the secretion of various gastrointestinal and pancreatic hormones.
### Primary Indications
* Treatment of symptoms associated with hormone-secreting tumors, such as carcinoid tumors and vasoactive intestinal peptide tumors (VIPomas).
* Management of acromegaly.
* Reduction of esophageal variceal bleeding in patients with cirrhosis.
### Adult Dosing
* **Hormone-secreting tumors:** Typically initiated at 0.1 mg subcutaneously (SC) every 8-12 hours. Dosing may be adjusted based on symptom control and hormone levels, often ranging from 0.1 mg to 0.5 mg SC every 8-12 hours. Intramuscular (IM) depot formulations are also available, with common initial doses of 10 mg or 20 mg IM every 4 weeks.
* **Acromegaly:** Initial dose is usually 10 mg to 30 mg IM every 4 weeks. Doses may be titrated up to 40 mg IM every 4 weeks based on IGF-1 levels.
* **Esophageal variceal bleeding:** Typically administered as a continuous intravenous (IV) infusion of 0.1 mg/hour for up to 48 hours.
### Pediatric Dosing
Dosing in pediatric patients is not well-established and should be determined by a specialist.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary, particularly in patients with severe hepatic impairment.
* **Renal Impairment:** No specific dose adjustments are typically required, but caution is advised.
### Contraindications
* Known hypersensitivity to octreotide or any component of the formulation.
### Adverse Effects
* **Common:** Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain, cramping), steatorrhea, flatulence.
* **Less Common:** Bradycardia, hyperglycemia, hypothyroidism, headache, dizziness, fatigue, injection site reactions.
* **Rare but Serious:** Cholelithiasis, pancreatitis, cardiac conduction abnormalities.
### Key Drug Interactions
* **Cyclosporine:** May decrease cyclosporine absorption, potentially leading to reduced efficacy of immunosuppression. Monitor cyclosporine levels.
* **Bromocriptine:** May increase bromocriptine levels.
* **Drugs affecting heart rate (e.g., beta-blockers):** Potential for additive bradycardic effects.
### Monitoring
* **Tumor markers and hormone levels:** To assess efficacy.
* **Symptom control:** Monitor for relief of symptoms related to hormone hypersecretion.
* **Blood glucose:** Monitor for hyperglycemia or hypoglycemia.
* **Thyroid function tests (TSH, free T4):** Monitor for hypothyroidism.
* **Liver function tests:** Monitor for hepatic effects.
* **Biliary system:** Consider ultrasound to monitor for gallstone formation.
* **ECG:** Consider in patients with pre-existing cardiac conditions or risk factors for QT prolongation.
### Clinical Pearls
* For SC administration, rotate injection sites to minimize discomfort and lipodystrophy.
* For IV infusion, dilute in an appropriate IV fluid and administer promptly.
* Long-acting IM formulations require regular administration every 4 weeks for sustained effect.
* Patients on long-term therapy may require monitoring for nutrient malabsorption.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and professional guidelines for complete details and to ensure patient safety.*
